Navigation Links
Keryx Biopharmaceuticals' Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
Date:9/14/2009

NEW YORK, Sept. 14 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Phase 2 data of KRX-0401 (perifosine), the Company's PI3K/Akt pathway inhibitor for cancer, as a single agent in the treatment of advanced metastatic renal cell cancer, has been selected for oral presentation at the Eighth International Kidney Cancer Symposium, to be held in Chicago from September 25-26, 2009.

Dr. Thomas E. Hutson, Director of the Genitourinary Oncology Program at Baylor-Sammons Cancer Center in Dallas, TX, will present Phase 2 results demonstrating perifosine's single agent efficacy in patients with metastatic renal cell carcinoma on Saturday, September 26th at 10:00 am CST, in a presentation entitled " Phase 2 study of perifosine in patients with metastatic renal cell carcinoma progressing after prior therapy with both a VEGF Receptor Inhibitor and an mTOR inhibitor."

This multi-center Phase 2 study was led by both Dr. Hutson and Dr. Nicholas Vogelzang, Chair and Medical Director of Developmental Therapeutics, Comprehensive Cancer Centers of Nevada / US Oncology Research. Drs. Hutson and Vogelzang also serve as co-chairs of the Genitourinary Committee for US Oncology Research. Data from this study was first presented by Dr. Vogelzang at the ASCO meeting in May 2009. Dr. Hutson's presentation will include updated information from the study.

About Renal Cell Carcinoma (RCC)

Of all kidney tumors, 85% are classified as renal cell carcinoma (RCC) and of all patients with RCC, 25% present with advanced disease. Advanced RCC is resistant to such standard treatments as radiation therapy and chemotherapy, and the initial treatment for most patients is surgical removal of the kidney. If the cancer is confined to th
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... Columbia and MENLO PARK, ... DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" ... developing and commercializing proven cancer therapies in new ... from its Phase I/II clinical trial of  VAL-083 ... the most common and deadly form of human ...
(Date:6/1/2015)... , June 1, 2015 CEFALY ... electrical nerve stimulation device specifically authorized for use prior ... data from a new PET trial showing that the ... in the brain in migraine patients, namely the orbitofrontal ... Tomography (PET) scan, which is an imaging test of the brain, used ...
(Date:6/1/2015)... June 1, 2015  Boston Biomedical, an industry leader ... cancer stem cell (CSC) pathways, will present clinical data ... multiple tumor types at the 2015 American Society of ... . Data presented at ASCO highlight ... that targets STAT3, leading to inhibition of the critical ...
Breaking Medicine Technology:DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 2DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 3DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 4DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 5DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 6DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 7DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 8New Study Shows CEFALY Returns Normal Metabolic Activity to Brain Areas in Migraine Patients 2Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 2Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 3Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 4Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 5Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 6Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 7
(Date:6/1/2015)... City, NY (PRWEB) June 02, 2015 ... honors Linda Cade as a 2015-2016 inductee ... is recognized with this prestigious distinction for leadership in ... for professional women, boasting more than 700,000 members and ... recognize Linda with this important honor,” said NAPW President ...
(Date:6/1/2015)... 02, 2015 The National Association ... Cornett, DSL, LSSBB (C), First Sergeant A Co., 15BSB ... of the Year Circle. She is recognized with this ... the nation's leading networking organization exclusively for professional women, ... Local Chapters. , “I'm pleased to recognize Sergeant Cornett ...
(Date:6/1/2015)... Ticket Down announces that the Golden State Warriors ... and now will face the Cleveland Cavaliers in the ... Oracle Arena in Oakland and the Quicken Loans Arena in ... season, the Golden State Warriors were the elite team that ... from their playoff failures from the year and riding the ...
(Date:6/1/2015)... CO (PRWEB) June 01, 2015 Atagi ... they have been named an Ultherapy® Ultra ... Plastic Surgery and Skin Aesthetics is one of only ... as a premier treatment provider. , Atagi Plastic ... in the Denver area has led the practice to ...
(Date:6/1/2015)... 2015 Rio Salado College’s Dental Clinic ... young adults this summer. , The clinics take place Friday, ... 3 p.m. at the Rio Salado Dental Clinic. The clinic ... “A big goal for us is to offer services to ... students,” said Nikki Shipp, Clinical Coordinator for Rio’s dental hygiene. ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Inducts Linda Cade, Senior Product Manager at Sage, Into its VIP Professional Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Lenita F. Cornett, First Sergeant of the US Military, Into its VIP Professional Woman of the Year Circle 2Health News:Warriors NBA Finals Tickets: 2015 NBA Finals Feature the Golden State Warriors vs. the Cleveland Cavaliers 2Health News:Warriors NBA Finals Tickets: 2015 NBA Finals Feature the Golden State Warriors vs. the Cleveland Cavaliers 3Health News:Atagi Plastic Surgery and Skin Aesthetics Named Ultherapy® Ultra Treatment Provider 2Health News:Kids Receive Complimentary Dental Services at Rio Salado Dental Clinic 2
... Dental Laser Market, SAN CLEMENTE, Calif., Feb. ... Inc. (Nasdaq: BLTI ) announced the,formation of ... laser,division, Lasers4Dentistry, and a laser therapy division,Technology4Therapy. Jeffrey ... and Keith G. Bateman, Biolase,s former Executive Vice ...
... Va., Feb. 21 Federal Health Information,Technology (IT) spending ... $4.5,billion in 2013 at a compound annual growth rate ... IT market, according to a new report by,INPUT, the ... robust, several things remain in the way of even,more ...
... and Water Reuse are Honored, NEW ... curricular solution for pharmacy education, has been,awarded ... Electronic Publication or,Product from the Professional/Scholarly Publishing ... In addition, the McGraw-Hill,reference, Water Reuse: Issues, ...
... release is available in Spanish . , ... Country, Maria Luisa de Francisco Maiz provided a clinical-forensic evaluation ... that influence the length of legal time periods. , Brain ... only for their high incidence but also because they mainly ...
... There are numerous antidepressant medications currently on ... the debilitating symptoms of depression even with treatment. ... 15th issue of Biological Psychiatry set out to ... serotonin and norepinephrine reuptake inhibitors (SNRIs), like venlafaxine ...
... . , Ikerlan-IK4 (CIC microGUNE Microfluidics Unit - ... device that enables the verification of the optimum conditions for ... a microelectrode that measures the impedance and temperature of the ... be monitored from the moment of its extraction, during its ...
Cached Medicine News:Health News:Former Biolase CEO & EVP Launch Technology4Medicine 2Health News:Federal Health IT Market to Reach $4.5 Billion by 2013 2Health News:McGraw-Hill Professional Products Win Awards From Association of American Publishers 2Health News:Guidelines for evaluation of psychological side-effects of brain injury 2Health News:Guidelines for evaluation of psychological side-effects of brain injury 3Health News:Comparison of venlafaxine and SSRIs in the treatment of depression 2Health News:A device that measures optimum state of an organ prior to transplanting has been patented 2
Used for temporary urine collection. The leg bag is designed for use with the Non-Adhesive Silicone Condom Catheter. Supplied non-sterile. Reusable. Intended for single patient use only....
The latex free, hydrophilic Self-Cath Plus is designed for single use, intermittent self-catheterization. The unique hydrophilic coating activates immediately upon exposure to water for fast, clean...
... is a latex-free unisex system that ... catheterization designed to reduce the risk ... includes a 100% latex-free Mentor Self-Cath ... tab makes it easy to use, ...
The latex free, hydrophilic Self-Cath Plus is designed for single use, intermittent self-catheterization. The unique hydrophilic coating activates immediately upon exposure to water for fast, clean...
Medicine Products: